1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Cimzia (Crohn’s Disease) - Forecast and Market Analysis to 2022

Cimzia (Crohn’s Disease) - Forecast and Market Analysis to 2022

Summary

The Crohn’s disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and efficacy profiles translate to clinical practice once they enter the market, their launch will be to the detriment of the existing market leaders, Remicade (infliximab) and Humira (adalimumab).The loss of patent protection of the anti-TNF marketed brands will allow for the emergence of biosimilars, such as Hospira’s Inflectra (infliximab) a Remicade biosimilar. Focusing on country dynamics, Canada and the emerging markets of China and India will also play a key role in driving growth in the long term, with each market forecast to post positive Compound Annual Growth Rates (CAGRs) from 2012 to 2022, primarily due to the anticipated strong uptake of Remicade over the forecast period.

UCB’s Cimzia (certolizumab pegol) is a PEGylated Fab' fragment of a humanized mAb with specificity for human TNF-?. The Fab' fragment of this biologic was engineered with a single free cysteine residue in the hinge region, which enables The site-specific attachment of polyethylene glycol without affecting the ability of the Fab' fragment to bind to and neutralize TNF-?. Due to the absence of the Fc region in its structure, Cimzia does not cause antibody-dependent, cell-mediated cytotoxicity. Also, in contrast to Remicade and Humira, Cimzia does not increase apoptosis, a well-known phenomenon with other anti-TNF-? agents, which may be responsible for their associated side effects.

Scope

- Overview of Crohn’s disease (CD), including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Cimzia including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Cimzia for the top seven countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, China and Canada

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Crohn’s disease
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Cimzia performance
- Obtain sales forecast for Cimzia from 2012-2022 in top seven countries (the US, France, Germany, Italy, Spain, China and Canada)

Table Of Contents

Cimzia (Crohn’s Disease) - Forecast and Market Analysis to 2022
1 Table of Contents

2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Related Reports 10
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 11
3.2 Symptoms 15
3.3 Prognosis 16
3.4 Quality of Life 16
4 Disease Management 17
4.1 Treatment Overview 18
5 Competitive Assessment 23
5.1 Overview 23
5.2 Strategic Competitor Assessment 24
6 Cimzia (certolizumab pegol) 26
6.1 Overview 26
6.2 Efficacy 27
6.3 Safety 27
6.4 SWOT Analysis 28
6.5 Forecast 29
7 Appendix 31
7.1 Bibliography 31
7.2 Abbreviations 34
7.3 Methodology 36
7.4 Forecasting Methodology 36
7.4.1 Diagnosed CD Patients 36
7.4.2 Percent Drug-Treated Patients 37
7.4.3 General Pricing Assumptions 37
7.4.4 Individual Drug Assumptions 39
7.4.5 Generic Erosion 39
7.5 Physicians and Specialists Included in This Study 40
7.6 Primary Research - Prescriber Survey 42
7.7 About the Authors 43
7.7.1 Author/Reviewer 43
7.7.2 Global Head of Healthcare 43
7.8 About GlobalData 44
7.9 Disclaimer 44

1.1 List of Tables

Table 1: Symptoms of CD 15
Table 2: Treatment Guidelines for CD 19
Table 3: Most Commonly Prescribed Drugs for CD in the Global Markets by Disease Severity, 2013 21
Table 4: Leading Branded Drugs Used to Treat CD 25
Table 5: Product Profile - Cimzia 27
Table 6: Cimzia SWOT Analysis, 2013 29
Table 7: Global Sales Forecasts ($) for Cimzia, 2012-2022 30
Table 8: Physicians Surveyed, By Country 42

1.2 List of Figures

Figure 1: Mucosa of the Bowel in a Healthy Individual (Left) and a Patient With CD (Right) 12
Figure 2: Potential Biologic Drug Targets for CD 14
Figure 3: Patient Care Path for CD 20

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
R&D Drug Pipeline Database: 1-Year Subscription

R&D Drug Pipeline Database: 1-Year Subscription

  • $ 6600
  • Industry report
  • November 2016
  • by La Merie Publishing

R&D Drug Pipeline Database: 1-Year Subscription Subscription to La Merie Publishing’s proprietary R&D Drug Pieline Database provides 24/7 online access to information about more than 21,000 project entries ...

Cancer Vaccines: Technologies and Global Markets

Cancer Vaccines: Technologies and Global Markets

  • $ 6650
  • Industry report
  • November 2016
  • by BCC Research

This cancer vaccines report by BCC Research explores present and future strategies within the market which includes prophylactic vaccines and therapeutic vaccines. Use this report to: - Analyze the global ...

Single-use Bioprocessing Market by Product, Application, End User - Global Forecast to 2021

Single-use Bioprocessing Market by Product, Application, End User - Global Forecast to 2021

  • $ 6328
  • Industry report
  • October 2016
  • by MarketsandMarkets

Rising Biopharmaceutical Demand and Increasing Investments in R&D Activities Drive Growth of the Single-use Bioprocessing Market The global single-use bioprocessing market is projected to reach USD 5.44 ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.